The 18 Wall Street analysts covering Definium Therapeutics, Inc. hold a median 12-month price target of $66 — +69.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 12 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Definium Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Growth (25): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (23): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DFTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +69.7% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Sept 2026 | RBC Capital | Reiterates | Outperform | $66 |
| 18 Aug 2026 | B of A Securities | Initiates | Buy | $75 |
| 18 Aug 2026 | B of A Securities | Initiates | Buy | — |
| 14 Aug 2026 | Maxim Group | Maintains | Buy | — |
| 13 Aug 2026 | Baird | Maintains | Outperform | — |
| 13 Aug 2026 | Baird | Maintains | Outperform | $57 → $75 |
| 13 Aug 2026 | Canaccord Genuity | Maintains | Buy | $58 → $64 |
| 13 Aug 2026 | Canaccord Genuity | Maintains | Buy | — |
| 13 Aug 2026 | Jones Trading | Maintains | Buy | $74 → $90 |
| 13 Aug 2026 | Jones Trading | Maintains | Buy | — |
| 13 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 13 Aug 2026 | RBC Capital | Maintains | Outperform | $57 → $66 |
| 13 Aug 2026 | Wells Fargo | Maintains | Overweight | — |
| 13 Aug 2026 | Wells Fargo | Maintains | Overweight | $68 → $72 |
| 12 Aug 2026 | Needham | Maintains | Buy | — |
| 12 Aug 2026 | Needham | Maintains | Buy | $50 → $66 |
| 7 Aug 2026 | Piper Sandler | Reiterates | Overweight | — |
| 7 Aug 2026 | Piper Sandler | Reiterates | Overweight | $73 → $75 |
| 27 July 2026 | Wells Fargo | Initiates | Overweight | $68 |
| 27 July 2026 | Wells Fargo | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DFTX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Definium Therapeutics, Inc. returned +303.0% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 18% of US stocks
Cheaper than 91% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 18% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Definium Therapeutics, Inc. has a market value of $5.2B and an enterprise value of $4.2B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$353.8M.
Free cash flow in the twelve months to 30 June 2026: −$168.0M.
Trailing P/E: −18.9×; forward P/E: −20.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Definium Therapeutics, Inc. employs 105 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Definium Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Definium Therapeutics released topline results from Panorama, its second Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet in adults with generalized anxiety disorder, describing the efficacy as "unprecedented."
Why it matters — A favorable reading from this Phase 3 trial could be an important step in the development of DFTX's lead anxiety drug candidate.
Definium Therapeutics announced positive topline results from Panorama, its second Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disorder (GAD). This marks the company's third late-stage study of the candidate.
Why it matters — A positive second Phase 3 readout represents a significant late-stage clinical milestone for DFTX's lead candidate DT120 in generalized anxiety disorder.
Definium Therapeutics announced inducement grants to three newly hired non-executive employees, consisting of options to purchase an aggregate of 56,650 common shares with effective grant dates of September 14.
Why it matters — The grants signal new employee hiring but involve option issuance that could represent share dilution for existing holders.
Definium Therapeutics announced it will present six poster presentations at Psych Congress 2026 in New Orleans, including topline data from its Phase 3 Emerge and Voyage trials across major depressive disorder and generalized anxiety disorder, as well as findings from its DT120 Orally Disintegrating Tablet Phase 3 clinical program.
Why it matters — DFTX watchers would care because the planned presentations of Phase 3 topline data represent a major clinical milestone for the company's lead psychiatric programs.
Definium Therapeutics announced that the U.S. FDA has granted Breakthrough Therapy designation for its investigational drug DT120 (lysergide) orally disintegrating tablet for major depressive disorder. The designation was supported by significant unmet medical need in MDD and results from the Company.
Why it matters — FDA Breakthrough Therapy designation could accelerate development and review of DT120 in MDD, a key pipeline asset for the company.
The 18 Wall Street analysts covering Definium Therapeutics, Inc. have a median 12-month price target of $66, with estimates ranging from $52 to $90. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 18 analysts covering Definium Therapeutics, Inc., 18 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Definium Therapeutics, Inc. 40 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Definium Therapeutics, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 18 analysts implies +69.7% from the last close, and Ticker Nerd's factor model ranks Definium Therapeutics, Inc. 40 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Definium Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DFTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $52 to $90 over the next 12 months.
Definium Therapeutics, Inc. returned +303.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Definium Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for brain health disorders.
The most recent item we track (Benzinga, 14 Sept 2026): "Definium Says Its Anxiety Drug Showed 'Unprecedented Efficacy'". Definium Therapeutics released topline results from Panorama, its second Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet in adults with generalized anxiety disorder, describing the efficacy as "unprecedented."
Definium Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for brain health disorders. The company’s current pipeline centers on psychiatry and neurology, with lead product candidates such as DT120, an orally disintegrating tablet under late-stage study for generalized anxiety disorder and major depressive disorder, and DT402, which is being evaluated for autism spectrum disorder. Definium Therapeutics applies a research-driven approach to psychedelic-derived and other brain-health-focused therapeutics, aiming to address underlying causes of psychiatric and neurological conditions. The company operates from New York and serves the healthcare and biotechnology markets through its drug development programs and clinical research activities.
CEO Mr. Robert Barrow · 105 employees · United States · https://definiumtx.com
